Fennec (FENC) CEO gets 200,000 options and new common shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
FENNEC PHARMACEUTICALS INC. reported that Chief Executive Officer Jeffrey S. Hackman received an incentive stock option grant to purchase 200,000 common shares at $5.77 per share, expiring on March 31, 2036, under the company’s 2020 Equity Incentive Plan.
On March 31, 2026, one-third of these options become exercisable, with additional portions vesting monthly so that all 200,000 options are vested by March 31, 2029. Hackman also acquired additional common shares through the settlement of performance share units that vested on March 31, 2026 and through the release of previously restricted shares awarded on March 28, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Hackman Jeffrey S.
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 200,000 | $5.77 | $1.15M |
| Exercise | Common Shares | 16,695 | $0.00 | -- |
| Exercise | Common Shares | 1,159 | $0.00 | -- |
| Exercise | Common Shares | 13,943 | $0.00 | -- |
Holdings After Transaction:
Stock Options — 725,000 shares (Direct);
Common Shares — 45,405 shares (Direct)
Footnotes (1)
- Represents settlement of PSUs that vested on March 31, 2026. Represents shares released from restriction from shares awarded 3/28/2025. On March 31, 2026, granted incentive stock options to purchase 200,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan. One-third of the shares subject to this option may be exercised as of March 31, 2027 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of March 31, 2029, 100% of the total number of shares subject to this option shall be vested.
Key Figures
Option grant size: 200,000 stock options
Option exercise price: $5.77 per share
Option expiration: March 31, 2036
+4 more
7 metrics
Option grant size
200,000 stock options
Granted March 31, 2026 under 2020 Equity Incentive Plan
Option exercise price
$5.77 per share
Incentive stock options granted March 31, 2026
Option expiration
March 31, 2036
Expiration date of 200,000 incentive stock options
Options after grant
725,000 options
Total stock options held following March 31, 2026 grant
PSU settlement shares
16,695 common shares
Common shares acquired March 31, 2026 via derivative exercise/conversion
Shares from released restriction
13,943 common shares
Common shares acquired March 28, 2026 via derivative exercise/conversion
Common shares after March 31, 2026
46,564 shares
Directly held common shares following one reported transaction on March 31, 2026
Key Terms
PSUs, incentive stock options, 2020 Equity Incentive Plan, Vesting Commencement Date, +1 more
5 terms
PSUs financial
"Represents settlement of PSUs that vested on March 31, 2026."
PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.
incentive stock options financial
"On March 31, 2026, granted incentive stock options to purchase 200,000 shares"
Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.
2020 Equity Incentive Plan financial
"pursuant to the Issuer's 2020 Equity Incentive Plan."
Vesting Commencement Date financial
"as of March 31, 2027 ("Vesting Commencement Date")."
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
FAQ
What insider transactions did FENC CEO Jeffrey Hackman report on this Form 4?
Jeffrey S. Hackman reported receiving an incentive stock option grant and acquiring common shares. The common shares came from performance share units that vested on March 31, 2026 and from shares released from restriction that were originally awarded on March 28, 2025.
How many stock options were granted to the FENC CEO and at what price?
The CEO received incentive stock options to purchase 200,000 common shares at $5.77 per share. These options were granted on March 31, 2026 under Fennec Pharmaceuticals’ 2020 Equity Incentive Plan, forming a significant component of his equity-based compensation.
When do Jeffrey Hackman’s new Fennec stock options vest and become exercisable?
One-third of the option grant becomes exercisable on March 31, 2027, the vesting commencement date. After that, one twenty-fourth of the options vests on the last day of each following month, so that all 200,000 options are fully vested by March 31, 2029.
What is the expiration date of the FENC CEO’s newly granted stock options?
The incentive stock options granted to the CEO expire on March 31, 2036. This long-dated expiration gives him a multi‑year window to exercise the options once vested, aligning his potential share ownership with the company’s longer-term performance.